Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,136 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

40,136 Papers indexed
1,440 Papers AI scored
40,136 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-11-06 10:15 AM
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40136 results
B
Ultrasound radiomics-based dynamic nomogram to predict histologic grade in soft tissue sarcoma: a multicenter cohort study.
PMID 40973073 Published: 2026-01-01 Ingested: 2026-08-02 12:06 AM The British journal of radiology
AI -
Standard 71.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 54.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 71.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 44.0; sample size: 90.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 71.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 44.0; sample size: 100.0; recency: 90.0; abstract quality: 100.0.

B
AI -
Standard 71.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 34.0; sample size: 80.0; recency: 90.0; abstract quality: 85.0.

B
Pathogenesis and Management of Intestinal Failure-Associated Liver Disease.
PMID 40015320 Published: 2025-02-27 Ingested: 2026-08-02 12:03 AM Seminars in liver disease
AI -
Standard 71.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 24.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

B
Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression.
PMID 39127699 Published: 2024-08-10 Ingested: 2026-08-02 12:02 AM Acta neuropathologica communications
AI -
Standard 71.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 24.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

B
Multimodality detection of tumour rupture in children with Wilms tumour.
PMID 39118247 Published: 2024-08-08 Ingested: 2026-08-02 12:01 AM Pediatric blood & cancer
AI -
Standard 71.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 54.0; sample size: 80.0; recency: 90.0; abstract quality: 100.0.

B
COVID-19 acts like a stress test, uncovering the vulnerable part of the human body: a retrospective study of 1640 cases in China.
PMID 38607985 Published: 2024-08-01 Ingested: 2026-08-02 12:02 AM European journal of public health
AI -
Standard 71.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 34.0; sample size: 90.0; recency: 80.0; abstract quality: 85.0.

B
AI -
Standard 71.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 54.0; sample size: 90.0; recency: 80.0; abstract quality: 100.0.

B
Transplacental pharmacokinetics and developmental toxicity of chemotherapeutic agents: a comparative analysis of fetal and pediatric exposure profiles.
PMID 42217211 Published: 2026-06-02 Ingested: 2026-08-02 12:07 AM Expert opinion on drug metabolism & toxicology
AI -
Standard 71.26
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 86.3; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

B
AI -
Standard 71.26
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 63.8; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

Previous
Page 594 of 3345
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic